Health · 2 views
Lp(a)-Lowering Pelacarsen Shows Huge Disconnect With Cardiovascular Outcomes
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 2 Community interest
Brief read Under 1 min brief 29 words
Summary
(MedPage Today) -- Lowering lipoprotein(a), or Lp(a), did not translate into better cardiovascular outcomes in a secondary prevention population, at least not with pelacarsen in the Lp(a) HORIZON trial.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Potential driver of severe early-onset preeclampsia identifiedContinue reading
- Avoiding Chemo in Breast Cancer; Psychedelic Medication for DepressionContinue reading
- Rise in NHS birth centre closures ‘shocking’ denial of women’s rights, experts sayContinue reading
- Retatrutide Is One Click Away. That Doesn't Make it Safe.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow